Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092930 - SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF

Publication Number WO/2020/092930
Publication Date 07.05.2020
International Application No. PCT/US2019/059435
International Filing Date 01.11.2019
IPC
A23L 33/105 2016.01
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
105Plant extracts, their artificial duplicates or their derivatives
A61K 31/404 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/522 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07D 209/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
04Indoles; Hydrogenated indoles
10with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
16Tryptamines
Applicants
  • RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY [US]/[US]
  • THE TRUSTEES OF PRINCETON UNIVERSITY [US]/[US]
Inventors
  • MOURADIAN, Mary, Maral
  • STOCK, Jeffry, B.
Agents
  • BUTCH, Peter, J.
  • BARRISON, Flynn
  • JOLIBOIS, Chipo
Priority Data
62/755,07402.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF
(FR) COMPOSITION SINERGIQUE PRÉSENTANT DES PROPRIÉTÉS NEUROPROTECTRICES ET SES PROCÉDÉS D'UTILISATION
Abstract
(EN)
A neuroprotective compositions containing caffeine or a caffeine analogue and a long chain fatty acyl tryptamide with an aliphatic chain having 16 to 22 carbons linked to a tryptamine, wherein the composition contains from at least 1.5 mg to 600 mg of caffeine per serving or unit dosage of the composition; from at least 0.5 mg to 300 mg of the long chain fatty acyl tryptamide per serving or unit dosage of the composition; and the ratio of long chain fatty acyl tryptamide to caffeine is from 1:1200 to 200:1. Methods are also disclosed for treating or preventing cognitive and movement deficits of a disease, condition or disorder or neurological deterioration that use the disclosed neuroprotective compositions.
(FR)
La présente concerne des compositions neuroprotectrices contenant de la caféine ou similaire et un acyle gras à longue chaîne tryptamide présentant une chaîne aliphatique présentant de 16 à 22 atomes de carbone liés à une tryptamine, la composition contenant d'au moins 1,5 mg à 600 mg de caféine par dose de service ou unitaire de la composition ; d'au moins 0,5 mg à 300 mg d'acyle gras à longue chaîne tryptamide par dose de service ou unitaire de la composition ; et le rapport entre l'acyle gras à longue chaîne tryptamide et la caféine étant de 1:200 à 200:1. L'invention concerne également des procédés permettant de traiter ou de prévenir des déficits cognitifs et de mouvement d'une maladie, d'une affection ou d'un trouble ou d'une détérioration neurologique qui utilisent les compositions neuroprotectrices selon l'invention.
Latest bibliographic data on file with the International Bureau